Rapid systemic and local treatments with the antibacterial peptide dimer A3-APO and its monomeric metabolite eliminate bacteria and reduce inflammation in intradermal lesions infected with Propionibacterium acnes and meticillin-resistant Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 42, Issue 6, 2013, Pages 537-543

  Ostorhazi, Eszter ^a   Voros, Elvira ^a   Nemes Nikodem, Eva ^a   Pinter, Dora ^a   Sillo, Palma ^a   Mayer, Balazs ^a   Wade, John D ^b,c   Otvos, Laszlo ^d  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Temple University   (United States)

Author keywords

Acne vulgaris; Bacterial counts; Burn injury; Cream formulation; Immunostimulation

Indexed keywords

A3 APO PEPTIDE; DRUG METABOLITE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERIAL LOAD; BURN INFECTION; COLONY FORMING UNIT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EAR INFECTION; FEMALE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; OTITIS; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROPIONIBACTERIUM ACNES INFECTION; SINGLE DRUG DOSE;

ACNE VULGARIS; BACTERIAL COUNTS; BURN INJURY; CREAM FORMULATION; IMMUNOSTIMULATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; INFLAMMATION; INJECTIONS, INTRAMUSCULAR; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; PEPTIDES; PROPIONIBACTERIUM ACNES; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME;

EID: 84889100021     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.08.001     Document Type: Article

References (30)

1. S.A. Li, W.H. Lee, and Y. Zhang Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models Antimicrob Agents Chemother 56 2012 3309 3317
2. K. Bush, M. Macielag, and M. Weidner-Wells Taking inventory: antibacterial agents currently at or beyond Phase 1 Curr Opin Microbiol 7 2004 466 476
3. A.K. Marr, W.J. Gooderham, and R.E.W. Hancock Antibacterial peptides for therapeutic use: obstacles and realistic outlook Curr Opin Pharmacol 6 2006 468 472
4. P. Czihal, D. Knappe, S. Fritsche, M. Zahn, N. Berthold, and S. Piantavigna Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens ACS Chem Biol 7 2012 1281 1291
5. A.M. van der Does, P.J. Hensbergen, S.J. Bogaards, M. Cansoy, A.M. Deelder, and H.C. van Leeuwen The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity J Immunol 188 2012 5012 5019
6. S. Welkos, C.K. Cote, U. Hahn, O. Shastak, J. Jedermann, and J. Bozue Humanized θ-defensins (retrocyclins) enhance macrophage performance and protect mice from experimental anthrax infections Antimicrob Agents Chemother 55 2011 4238 4250
7. R. Capparelli, F. De Chiara, N. Nocerino, R.C. Montella, M. Iannaccone, and A. Fulgione New perspectives for natural antimicrobial peptides: application as anti-inflammatory drugs in a murine model BMC Immunol 13 2012 61
8. P.B. Noto, G. Abbadessa, M. Cassone, G.D. Mateo, A. Agelan, and J.D. Wade Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo Protein Sci 17 2008 1249 1255
9. D. Szabo, E. Ostorhazi, A. Binas, F. Rozgonyi, B. Kocsis, and M. Cassone The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models Int J Antimicrob Agents 35 2010 357 361
10. E. Ostorhazi, F. Rozgonyi, D. Szabo, A. Binas, M. Cassone, and J.D. Wade Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections Biopolymers 96 2011 126 129
11. E. Ostorhazi, F. Rozgonyi, A. Sztodola, F. Harmos, I. Kovalszky, and D. Szabo Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections J Antimicrob Chemother 65 2010 2416 2422
12. E. Ostorhazi, M.C. Holub, F. Rozgonyi, F. Harmos, M. Cassone, and J.D. Wade Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved Int J Antimicrob Agents 37 2011 480 484
13. F. Baquero Gram-positive resistance: challenge for the development of new antibiotics J Antimicrob Chemother 39 Suppl A 1997 1 6
14. M. Ozolins, E.A. Eady, A. Avery, W.J. Cunliffe, C. O'Neill, and N.B. Simpson Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne Health Technol Assess 9 2005 iii iii212
15. T. Yamakawa, J. Mitsuyama, and K. Hayashi In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone J Antimicrob Chemother 49 2002 455 465
16. L. Otvos Jr., J.D. Wade, F. Lin, B.A. Condie, J. Hanrieder, and R. Hoffmann Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates J Med Chem 48 2005 5349 5359
17. P-F. Liu, T. Nakatsuji, W. Zhu, R.L. Gallo, and C.M. Huang Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris Vaccine 29 2011 3230 3238
18. R. Shames, F. Satti, E.M. Velozzi, and M.A. Smith Susceptibilities of Propionibacterium acnes ophthalmic isolates to ertapenem, meropenem and cefepime J Clin Microbiol 44 2006 4227 4228
19. Y. Olutunmbi, and K. Paley English JC III. Adolescent female acne: etiology and management J Pediatr Adolesc Gynecol 21 2008 171 176
20. Y. Wang, Z. Zhang, L. Chen, H. Guang, Z. Li, and H. Yang Cathelicidin-BF, a snake cathelicidin-derived antimicrobial peptide, could be an excellent therapeutic agent for acne vulgaris PLoS One 7 2011 e22120
21. 2 J Biol Chem 280 2005 1336 1345
22. P.J. Leenen, M.F. deBruijn, J.S. Voerman, P.A. Campbell, and W. van Ewijk Markers of mouse macrophage development detected by monoclonal antibodies J Immunol Methods 174 1994 5 19
23. D.M. Bowdish, D.J. Davidson, Y.E. Lau, K. Lee, M.G. Scott, and R.E. Hancock Impact of LL-37 on anti-infective immunity J Leukoc Biol 77 2005 451 459
24. P.H. Lee, J.A. Rusisill, K.H. Lin, L. Zhang, S.M. Harris, and T.J. Falla HB-107, a nonbacteriostatic fragment of the antibacterial peptide cecropin B, accelerates murine wound repair Wound Repair Regen 12 2004 351 358
25. A. Som, N. Navasa, A. Percher, R.W. Scott, G.N. Tew, and J. Anguita Identification of synthetic host defense peptide mimics that exert dual antimicrobial and anti-inflammatory activities Clin Vaccine Immunol 19 2012 1784 1791
26. A. Nijnik, L. Madera, S. Ma, M. Waldbrook, M.R. Elliott, and D.M. Easton Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment J Immunol 184 2010 2539 2550
27. M.M. Guarna, R. Coulson, and E. Rubinchik Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris FEMS Microbiol Lett 257 2006 1 6
28. S. Popovic, E. Urban, M. Lukic, and J.M. Conlon Peptides with antimicrobial and anti-inflammatory activities that have therapeutic potential for treatment of acne vulgaris Peptides 34 2012 275 282
29. M. Cassone, N. Frith, P. Vogiatzi, J.D. Wade, and L. Otvos Jr. Induced resistance to the designer proline-rich antimicrobial peptide A3-APO does not involve changes in the intracellular target DnaK Int J Pept Res Ther 15 2009 121 128
30. N.Y. Yount, and M.R. Yeaman Emerging themes and therapeutic prospects for anti-infective peptides Annu Rev Pharmacol Toxicol 52 2012 337 360